Q2 EPS Estimate for Fate Therapeutics Raised by Analyst

Fate Therapeutics, Inc. (NASDAQ:FATE) – Analysts at HC Wainwright boosted their Q2 2026 earnings per share estimates for shares of Fate Therapeutics in a research report issued to clients and investors on Monday, June 8th. HC Wainwright analyst R. Burns now forecasts that the biopharmaceutical company will post earnings per share of ($0.27) for the quarter, up from their previous estimate of ($0.29). HC Wainwright has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Fate Therapeutics’ current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for Fate Therapeutics’ Q3 2026 earnings at ($0.28) EPS, Q4 2026 earnings at ($0.28) EPS and FY2026 earnings at ($1.09) EPS.

A number of other analysts have also recently issued reports on FATE. Jefferies Financial Group set a $4.00 target price on Fate Therapeutics in a research note on Tuesday, May 19th. Weiss Ratings raised shares of Fate Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, May 13th. Three research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $5.13.

Fate Therapeutics Price Performance

NASDAQ:FATE opened at $1.90 on Wednesday. The business’s 50-day simple moving average is $1.76 and its 200-day simple moving average is $1.37. Fate Therapeutics has a fifty-two week low of $0.91 and a fifty-two week high of $2.88. The stock has a market capitalization of $221.46 million, a PE ratio of -1.74 and a beta of 2.53.

Fate Therapeutics (NASDAQ:FATE) last posted its earnings results on Wednesday, May 13th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.03. Fate Therapeutics had a negative return on equity of 58.89% and a negative net margin of 2,056.79%.The firm had revenue of $1.30 million during the quarter, compared to analysts’ expectations of $1.49 million.

Hedge Funds Weigh In On Fate Therapeutics

Several hedge funds have recently made changes to their positions in FATE. Bank of America Corp DE raised its holdings in shares of Fate Therapeutics by 24.8% in the first quarter. Bank of America Corp DE now owns 188,564 shares of the biopharmaceutical company’s stock valued at $226,000 after purchasing an additional 37,457 shares during the last quarter. Irenic Capital Management LP acquired a new position in shares of Fate Therapeutics during the 1st quarter worth about $1,054,000. Renaissance Technologies LLC grew its holdings in shares of Fate Therapeutics by 26.0% in the 1st quarter. Renaissance Technologies LLC now owns 2,974,683 shares of the biopharmaceutical company’s stock valued at $3,570,000 after acquiring an additional 613,802 shares in the last quarter. Bruce & Co. Inc. grew its stake in shares of Fate Therapeutics by 8.2% in the first quarter. Bruce & Co. Inc. now owns 789,188 shares of the biopharmaceutical company’s stock valued at $947,000 after buying an additional 60,000 shares in the last quarter. Finally, Sei Investments Co. increased its position in Fate Therapeutics by 104.9% during the first quarter. Sei Investments Co. now owns 138,580 shares of the biopharmaceutical company’s stock worth $166,000 after buying an additional 70,937 shares during the last quarter. 97.54% of the stock is owned by institutional investors.

Insider Activity

In related news, insider Cindy Tahl sold 25,590 shares of Fate Therapeutics stock in a transaction that occurred on Wednesday, May 20th. The stock was sold at an average price of $1.88, for a total value of $48,109.20. Following the sale, the insider owned 628,155 shares of the company’s stock, valued at approximately $1,180,931.40. This trade represents a 3.91% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 4.74% of the company’s stock.

About Fate Therapeutics

Fate Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of first‐in‐class cellular immunotherapies for cancer and immune disorders. The company leverages its proprietary induced pluripotent stem cell (iPSC) platform to create off‐the‐shelf natural killer (NK) and T‐cell products designed to overcome limitations of donor‐derived approaches. Fate’s research aims to deliver therapies with consistent quality, increased potency and scalable manufacturing for broad patient access.

Central to Fate’s pipeline are multiple iPSC‐derived cell therapy candidates in active clinical development.